Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tight control biologic dose reduction in psoriasis with low disease activity
NL-OMON42814Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab, etanercept and ustekinumab in plaque psoriasis (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Psoriasis Area and Severity Index at 12 months. Started Mar 2016; status: active, not recruiting.
02
Drugs
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NL-OMON42814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42814.